SVLSF VI, LLC Buys 89,783 TRex Bio Shares at $14 – A Premium Stake Signals Growing Institutional Confidence in the Biotech’s Clinical Pipeline
SVLSF VI’s recent bulk purchase of TRex Bio shares signals strong institutional faith in its clinical pipeline, potentially boosting liquidity and investor confidence.
4 minutes to read